EUKON Legality Rating awarded
Caserta, ITALY – 03 Feb 2026 Legality Rating awarded 🚀…
Gender matter! EUKON move on mission 5
Caserta, ITALY – August 8th, 2023 We are absolutely…
FAVOR III China: QFR-Guided PCI Strategy vs. Angiography-Guided Strategy
FAVOR III China has bees published on Lancet and simultaneously presented at TCT 2021
It’s the first randomized trial to compare the clinical outcomes of PCI guided by angiography-derived physiological lesion selection and standard angiography-guided lesion selection. QFR guidance resulted in a 35% risk reduction in the 1-year rate of major adverse cardiac events, a composite of death from any cause, myocardial infarction, or ischaemia driven revascularization, compared with standard angiography guidance. READ MORE
Latest News:
EUKON FT1000 ranking 2022 on Financial Times
FT 1000: the sixth annual list of Europe’s fastest-growing companies…